Antibodies
24 January 2024
Biosion Announces FDA Clearance of IND Application for BSI-082, a Novel Anti-SIRPα Monoclonal Antibody23 January 2024
CDR-Life Announces FDA Clearance of IND Application for CDR404 for Treatment of Solid Tumors23 January 2024
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity23 January 2024
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline22 January 2024
Gilead Provides Update on Phase 3 EVOKE-01 Study22 January 2024
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market22 January 2024
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer18 January 2024
AskGene Presents Interim Results of ASKB589 (anti-CLDN18.2 antibody) in Combination with CAPOX and PD-1 Inhibitor at ASCO-GI 202417 January 2024
Glypican-3 (GPC3): a novel and promising target for immunotherapy of hepatocellular carcinomaNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports